UNSPSC 51123103: Droxicainide

This classification denotes an antiarrhythmic agent with the molecular formula C16H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) J6W196LMV3, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-n-(2-hydroxyethyl)-, monohydrochloride, (+-)- but more generally known as droxicainide, which bears US NIH Compound Identifier 135791. European Medicines Agency schedules Droxicainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06418MIG.

UNSPSC 51123103 Droxicainide is a Commodity code encompassing pharmaceutical products supplied to state and local healthcare and emergency-response agencies. State and local governments procure emergency medications and specialty pharmaceuticals under this code for use by fire rescue services, hospital systems, and public health programs. Recent solicitations show purchasing of advanced life support medications in unit quantities typically ranging from 300 to 1,800 units per line item, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and expiration-date warranties extending nine months to one year from delivery. Issuing bodies include city fire departments, state health and human services agencies, and multistate cooperative purchasing alliances. The City of Tampa Fire Rescue and the Texas Health and Human Services Commission represent recent activity; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinates purchases across multiple state and local facilities including Oregon. Cooperative purchasing vehicles like MMCAP aggregate demand across jurisdictions and distribute awarded vendors to authorized wholesalers.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. The City of Tampa issued an IFB (26P00188) in April 2026 for advanced life support medications—Labetalol, Epinephrine, Adenosine, and Diltiazem—with a response deadline of April 8, 2026 and an estimated contract value of $40,000, with a one-year term and two optional one-year renewals plus three 30-day extensions; the solicitation included a Small Local Business Enterprise (SLBE) sheltered market designation with a 5 percent bid discount capped at $10,000. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026 and a two-year initial contract term; vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen / Cencora, Cardinal Health, Morris & Dickson) and agree to a 3 percent administrative fee, with price competitiveness weighted at 75 percent of evaluation. The Texas HHS Commission issued an RFI (HHS0017013) in April 2026 seeking market intelligence on direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, signaling exploratory-phase procurement that will likely lead to formal RFP activity.